AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) gapped up prior to trading on Friday . The stock had previously closed at $0.89, but opened at $0.93. AVEO Pharmaceuticals shares last traded at $1.08, with a volume of 18583059 shares.
A number of brokerages have weighed in on AVEO. B. Riley reissued a “neutral” rating and set a $1.00 price objective (down previously from $5.00) on shares of AVEO Pharmaceuticals in a report on Monday, February 4th. HC Wainwright downgraded shares of AVEO Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $1.00 price target on the stock. in a report on Friday, February 1st. National Securities began coverage on shares of AVEO Pharmaceuticals in a research report on Thursday, March 28th. They issued a “sell” rating for the company. ValuEngine cut shares of AVEO Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 31st. Finally, FBR & Co set a $3.00 target price on shares of AVEO Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, December 20th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company’s stock. AVEO Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $1.96.
A number of institutional investors have recently added to or reduced their stakes in the business. Two Sigma Securities LLC purchased a new stake in shares of AVEO Pharmaceuticals in the fourth quarter worth $28,000. Chicago Equity Partners LLC purchased a new stake in AVEO Pharmaceuticals during the 4th quarter valued at about $32,000. Albion Financial Group UT purchased a new stake in AVEO Pharmaceuticals during the 4th quarter valued at about $38,000. Two Sigma Advisers LP increased its stake in AVEO Pharmaceuticals by 7.2% during the 4th quarter. Two Sigma Advisers LP now owns 422,000 shares of the biopharmaceutical company’s stock valued at $675,000 after purchasing an additional 28,500 shares in the last quarter. Finally, Northern Trust Corp increased its stake in AVEO Pharmaceuticals by 3.0% during the 4th quarter. Northern Trust Corp now owns 1,175,604 shares of the biopharmaceutical company’s stock valued at $1,882,000 after purchasing an additional 34,164 shares in the last quarter. 35.72% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: “AVEO Pharmaceuticals (AVEO) Shares Gap Up to $0.93” was posted by Modern Readers and is owned by of Modern Readers. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The correct version of this report can be read at https://www.modernreaders.com/news/2019/04/07/aveo-pharmaceuticals-aveo-shares-gap-up-to-0-93.html.
About AVEO Pharmaceuticals (NASDAQ:AVEO)
AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).
Further Reading: What is Put Option Volume?
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.